ArticleMaterials today. Bio2026
Rewiring diabetic abscess microenvironment for healing via CeMo-mediated photothermal antibacterial, ROS scavenging and immunomodulatory.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic abscesses represent a severe and challenging complication of chronic wounds, characterized by impaired healing due to hyperglycemia-induced oxidative stress, persistent inflammation, and susceptibility to infection. Despite advances in wound care, effective therapeutic strategies that simultaneously address these multifactorial pathologies remain lacking. Herein, we developed cerium molybdate nanoparticles (CeMo) through a green one-pot method as multifunctional therapeutic platforms for diabetic abscess treatment. CeMo exhibited dual enzyme-mimetic activities, serving as superoxide dismutase and catalase to catalytically eliminate reactive oxygen species (ROS) with over 90% scavenging efficiency at 100 μg/mL. Furthermore, they demonstrated exceptional photothermal conversion efficiency with a 30% conversion efficiency under 808 nm laser irradiation, enabling effective disruption of methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.